Many patients do not realize that weight-loss medications require special perioperative consideration, so explicit disclosure is critical even if not directly asked
13 Treatment groups Experimental Treatment Placebo Group Part A Randomized 1:1 Part B Sema, high dose trevo, and gareto followed by high dose trevo Randomized 1:1:1:1:1:1:1:1 Part B Sema, high dose trevo, and garetosmab (gareto) followed by SC placebo Randomized 1:1:1:1:1:1:1:1 Part B Sema, high dose trevo, and IV placebo followed by high dose trevo Randomized 1:1:1:1:1:1:1:1 Part B Sema, high dose trevo, and IV placebo followed by SC placebo Randomized 1:1:1:1:1:1:1:1 Part B Sema, moderate-high dose trevo, and IV placebo followed by high dose trevo Randomized 1:1:1:1:1:1:1:1 Part B Sema, moderate-high dose trevo, and IV placebo followed by SC placebo Randomized 1:1:1:1:1:1:1:1 Part B Sema and SC placebo and IV placebo followed by high dose trevogrumab (trevo) Randomized 1:1:1:1:1:1:1:1 Part B Semaglutide (sema) and subcutaneous (SC) placebo and intravenous (IV) placebo followed by SC placebo Randomized 1:1:1:1:1:1:1:1 Part C Sema and SC moderate dose trevo Randomized 1:2:2 Part C Sema and SC low dose trevo Randomized 1:2:2 Part C Sema and SC placebo Randomized 1:2:2 Part A Randomized 1:1 Find a Clinic Near You Who Is Running the Clinical Trial
We cannot promise a specific number, because individual results vary widely based on starting weight, adherence, dose tolerance, and lifestyle factors
Maybe ready to try it for yourself or at least schedule a consultation to learn more By booking a consultation with Dr
Some people notice stronger appetite suppression right away because of the GIP component
